Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Analgesia
EpiCept announces additional findings from LidoPAIN SP European Phase III clinical trial
October 25th, 2006
EpiCept Corporation (EPCT) announced several important findings revealed from an ongoing analysis of its previously reported Phase III clinical trial results for LidoPAIN SP, the company's sterile prescription analgesic patch designed to provide sustained topical delivery of lidocaine to a post-surgical or post-traumatic sutured wound. The company is studying the impact of these findings in conjunction with other data generated from the trial in order determine what changes in trial design could be made to improve the likelihood of a positive result in a subsequent trial. The multicenter, randomized, double blind, placebo controlled, Phase III trial...
Source: Biotech Week (2006-10-25)
|
